Personalized Dyslipidemia Treatment Systems via Synergistic Combinations

Integrating pemafibrate dosing regimens with AI, IoT, blockchain, and novel materials to create a more effective and personalized treatment system for dyslipidemia

The original pemafibrate dosing regimens, while effective, have limitations in terms of individual patient responses and treatment outcomes. This new inventive concept addresses these limitations by combining pemafibrate with distinct technologies to create a more powerful and personalized treatment system.

The new inventive concept comprises a pemafibrate dosing regimen module integrated with an AI-powered patient data analytics platform to optimize pemafibrate dosage based on individual patient responses. Additionally, IoT-enabled wearable devices and machine learning algorithms are used for real-time monitoring of pemafibrate efficacy. A blockchain-based secure data storage system is employed for pemafibrate treatment outcomes, enabling secure sharing of patient data with healthcare providers and researchers. Furthermore, a pemafibrate-based pharmaceutical composition incorporating a novel, biodegradable material for sustained release of pemafibrate is used. A machine learning model trained on a dataset of OATP1B inhibitor interactions is used to predict pemafibrate-drug interactions, enabling personalized medicine.

The new inventive concept's integration of pemafibrate dosing regimens with AI, IoT, blockchain, and novel materials constitutes a non-obvious and novel combination that provides a more effective and personalized treatment system for dyslipidemia. The use of machine learning algorithms, blockchain, and novel materials in this context is particularly innovative and provides a significant improvement over the original pemafibrate dosing regimens.

Alternative embodiments of the inventive concept could include the use of different AI algorithms, IoT devices, or blockchain platforms. Additionally, the pemafibrate-based pharmaceutical composition could be modified to incorporate different biodegradable materials or release mechanisms. The machine learning model could be trained on different datasets or used in conjunction with other predictive analytics tools.

The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the area of personalized medicine. The target market includes healthcare providers, researchers, and patients with dyslipidemia. The inventive concept's ability to provide more effective and personalized treatment outcomes could lead to increased adoption and market share.